Video Insights
Video Insights
Advertisement
David Braun, MD, PhDAdvanced Renal Cell Carcinoma | April 22, 2024
Drs. Braun and Beckermann stress the importance of adopting an integrative approach to biomarker-based research in RCC.
View More
David Braun, MD, PhDAdvanced Renal Cell Carcinoma | April 22, 2024
Drs. Braun and Beckermann review JAVELIN Renal 101, focusing on the impact of avelumab and axitinib treatment on RCC.
David Braun, MD, PhDAdvanced Renal Cell Carcinoma | April 22, 2024
Drs. Braun and Beckermann discuss the evolving significance of sarcomatoid histology in guiding treatment decisions for RCC.
Veronica Mollica, MDTesticular, Penile, and Rare Malignancies | April 19, 2024
Dr. Mollica continues her discussion on prognostic factors and clinical outcomes in PSCC.
Veronica Mollica, MDTesticular, Penile, and Rare Malignancies | April 19, 2024
Dr. Mollica highlights her recent research investigating prognostic factors and clinical outcomes for patients with PSCC.
Matthew Galsky, MDMuscle Invasive Urothelial Carcinoma | April 18, 2024
Dr. Galsky shares the first OS data update on the CheckMate 274 trial, which he gave at the 2024 EAU Congress.
Monika Joshi, MD, MRCPAdvanced Urothelial Carcinoma | April 17, 2024
Dr. Joshi contextualizes the THOR study within the treatment landscape for FGFR2/3-altered advanced urothelial carcinoma.
Andrei Iagaru, MDProstate Cancer Diagnostics | April 16, 2024
Dr. Iagaru discusses the safety findings and clinical implications of his research.
Gary Ulaner, MD, PhD, FSNMMI, FACNMProstate Cancer Diagnostics | April 16, 2024
Dr. Ulaner highlights 2 new clinical trials for prostate cancer staging and treatment at Hoag: MIRROR and 177Lu-PNT2002.
Michael B. Atkins, MDAdvanced Renal Cell Carcinoma | April 11, 2024
Drs. Atkins and Beckermann weigh the potential of targeting Tregs in RCC treatment, particularly in relation to PD-1 therapy.
Michael B. Atkins, MDAdvanced Renal Cell Carcinoma | April 11, 2024
Drs. Atkins and Beckermann consider biomarkers for patient selection for LAG-3 inhibition and increasing cure rates in RCC.
Michael B. Atkins, MDAdvanced Renal Cell Carcinoma | April 11, 2024
Drs. Atkins and Beckermann discuss LAG-3 as a novel checkpoint inhibitor combined with anti-PD-1 for kidney cancer.cC
Guy Verhovsky, MDUrothelial Carcinoma | April 11, 2024
Drs. Grasso and Verhovsky discuss the potential of endoscopic treatment with surveillance for patients with bladder cancer.
Amanda Myers, MDNon-Muscle Invasive Urothelial Carcinoma | April 9, 2024
Dr. Myers and colleagues challenge the current paradigm of discouraging additional BCG therapy for "unresponsive" NMIBC.
Steven Canfield, MDLocalized | April 9, 2024
Dr. Canfield shares real-world active surveillance among men with localized PC tested with the genomic prostate score assay.
Daniel Spratt, MDLocalized | April 5, 2024
Dr. Spratt reviews the safety and efficacy of relugolix plus RT in patients with localized or advanced prostate cancer.
James “Jed” Ferguson III, MD, PhDUpper Tract Urothelial Carcinoma | March 29, 2024
Dr. Ferguson sheds light on a national analysis evaluating the role of lymph node dissection in patients with high-risk UTUC.
James “Jed” Ferguson III, MD, PhDNon-Muscle Invasive Urothelial Carcinoma | March 29, 2024
Dr. Ferguson highlights the latest TAR-210 and TAR-200 data in select patients with non-muscle invasive bladder cancer.
Jérémie Calais, MD, PhDProstate Cancer Diagnostics | March 21, 2024
The panel continues discussing their phase 3 PSMA PET/CT trial expectations for the final data readout in 2025.
Jérémie Calais, MD, PhDProstate Cancer Diagnostics | March 21, 2024
The panel from UCLA highlights their study on the impact of PSMA PET/CT on prostate cancer salvage radiotherapy management.
Advertisement
Advertisement
Advertisement